Eli Lilly and Company has launched Lormalzi (donanemab), a new treatment specifically for early Alzheimer's disease, in India. Priced at ₹91,688 for a 350 mg vial, this therapy is administered via intravenous infusion once a month and targets amyloid plaques in the brain, which are linked to cognitive decline. The Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization for Lormalzi, marking it as the first once-monthly amyloid-targeting therapy available in India. The launch addresses a growing dementia crisis in India, where approximately 8.8 million people are affected, a number expected to nearly double by 2036. Experts emphasize the importance of early diagnosis and specialized testing to ensure effective treatment, as not all patients with memory issues qualify for this therapy. Concerns regarding the drug's safety, including potential amyloid-related imaging abnormalities (ARIA), highlight the need for careful monitoring. Despite its promise, the high cost may hinder access for many families, posing a significant challenge in the fight against Alzheimer's in India.